Logo image of ALSEN.PA

SENSORION SA (ALSEN.PA) Stock Fundamental Analysis

EPA:ALSEN - Euronext Paris - Matif - FR0012596468 - Common Stock - Currency: EUR

0.383  -0.02 (-5.2%)

Fundamental Rating

3

Overall ALSEN gets a fundamental rating of 3 out of 10. We evaluated ALSEN against 73 industry peers in the Biotechnology industry. While ALSEN seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ALSEN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALSEN had negative earnings in the past year.
In the past year ALSEN has reported a negative cash flow from operations.
In the past 5 years ALSEN always reported negative net income.
In the past 5 years ALSEN always reported negative operating cash flow.
ALSEN.PA Yearly Net Income VS EBIT VS OCF VS FCFALSEN.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

ALSEN has a Return On Assets of -29.09%. This is comparable to the rest of the industry: ALSEN outperforms 52.05% of its industry peers.
ALSEN has a Return On Equity (-36.00%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -29.09%
ROE -36%
ROIC N/A
ROA(3y)-45.38%
ROA(5y)-34.99%
ROE(3y)-69.45%
ROE(5y)-51.62%
ROIC(3y)N/A
ROIC(5y)N/A
ALSEN.PA Yearly ROA, ROE, ROICALSEN.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

ALSEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALSEN.PA Yearly Profit, Operating, Gross MarginsALSEN.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALSEN has more shares outstanding
Compared to 5 years ago, ALSEN has more shares outstanding
ALSEN has a better debt/assets ratio than last year.
ALSEN.PA Yearly Shares OutstandingALSEN.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
ALSEN.PA Yearly Total Debt VS Total AssetsALSEN.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 2.98 indicates that ALSEN is not a great score, but indicates only limited risk for bankruptcy at the moment.
ALSEN's Altman-Z score of 2.98 is fine compared to the rest of the industry. ALSEN outperforms 73.97% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ALSEN is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.01, ALSEN is doing good in the industry, outperforming 76.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 2.98
ROIC/WACCN/A
WACCN/A
ALSEN.PA Yearly LT Debt VS Equity VS FCFALSEN.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 6.28 indicates that ALSEN has no problem at all paying its short term obligations.
ALSEN has a Current ratio of 6.28. This is amongst the best in the industry. ALSEN outperforms 84.93% of its industry peers.
A Quick Ratio of 6.28 indicates that ALSEN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.28, ALSEN belongs to the top of the industry, outperforming 86.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.28
Quick Ratio 6.28
ALSEN.PA Yearly Current Assets VS Current LiabilitesALSEN.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.21% over the past year.
EPS 1Y (TTM)55.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 42.31% on average over the next years. This is a very strong growth
ALSEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 66.94% yearly.
EPS Next Y11.11%
EPS Next 2Y18.64%
EPS Next 3Y14.47%
EPS Next 5Y42.31%
Revenue Next Year95.58%
Revenue Next 2Y47.68%
Revenue Next 3Y15.46%
Revenue Next 5Y66.94%

3.3 Evolution

ALSEN.PA Yearly Revenue VS EstimatesALSEN.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
ALSEN.PA Yearly EPS VS EstimatesALSEN.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALSEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALSEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALSEN.PA Price Earnings VS Forward Price EarningsALSEN.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALSEN.PA Per share dataALSEN.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2

4.3 Compensation for Growth

A more expensive valuation may be justified as ALSEN's earnings are expected to grow with 14.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.64%
EPS Next 3Y14.47%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALSEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SENSORION SA

EPA:ALSEN (6/17/2025, 7:00:00 PM)

0.383

-0.02 (-5.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-14 2025-03-14/amc
Earnings (Next)09-16 2025-09-16
Inst Owners53.64%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap115.15M
Analysts86.67
Price Target2.21 (477.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.77%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)36.84%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)128.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.6
P/tB 1.61
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.09%
ROE -36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.38%
ROA(5y)-34.99%
ROE(3y)-69.45%
ROE(5y)-51.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.28
Quick Ratio 6.28
Altman-Z 2.98
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)191.05%
Cap/Depr(5y)144.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.9%
EPS Next Y11.11%
EPS Next 2Y18.64%
EPS Next 3Y14.47%
EPS Next 5Y42.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year95.58%
Revenue Next 2Y47.68%
Revenue Next 3Y15.46%
Revenue Next 5Y66.94%
EBIT growth 1Y-27.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.76%
EBIT Next 3Y13.96%
EBIT Next 5Y38.57%
FCF growth 1Y-0.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.23%
OCF growth 3YN/A
OCF growth 5YN/A